Literature DB >> 1887131

Inflammatory markers in cystic fibrosis.

R J Rayner1, M S Wiseman, S M Cordon, D Norman, E J Hiller, D J Shale.   

Abstract

Plasma neutrophil elastase-alpha 1 antiproteinase complex, lactoferrin and C-reactive protein (CRP) were determined over a 15-month period in 26 patients with cystic fibrosis, of whom 21 were chronically infected with Pseudomonas aeruginosa. Median concentrations of both neutrophil products and CRP were greater in patients who were clinically stable than in healthy subjects without cystic fibrosis. CRP concentrations increased further at the onset of symptomatic exacerbations. Thirty-five courses of intravenous antibiotics and 22 courses of oral ciprofloxacin were reviewed and revealed similar improvements in clinical scores and lung function tests for both forms of treatment. Intravenous antibiotics reduced the plasma concentrations of both neutrophil products and CRP, while oral ciprofloxacin only significantly reduced the concentration of neutrophil elastase-alpha 1 antiproteinase complex. Plasma concentrations of inflammatory markers were significantly greater in exacerbations associated with fever and leukocytosis. Statistical modelling demonstrated negative within-patient relationships between lung function and both CRP and lactoferrin, and positive relationships between the three inflammatory markers. Neutrophil granule products and CRP reflect the pulmonary inflammatory state in cystic fibrosis and may be of value in monitoring treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1887131     DOI: 10.1016/s0954-6111(06)80292-1

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  13 in total

Review 1.  Microbiology of cystic fibrosis lung infections: themes and issues.

Authors:  J R Govan; J W Nelson
Journal:  J R Soc Med       Date:  1993       Impact factor: 5.344

2.  Inflammatory markers of lung disease in adult patients with cystic fibrosis.

Authors:  Hara Levy; Leslie A Kalish; Ian Huntington; Nathaniel Weller; Craig Gerard; Edwin K Silverman; Juan C Celedón; Gerald B Pier; Scott T Weiss
Journal:  Pediatr Pulmonol       Date:  2007-03

Review 3.  Clinical management of children and adults with cystic fibrosis.

Authors:  A K Webb; T J David
Journal:  BMJ       Date:  1994-02-12

4.  Intestinal inflammation in cystic fibrosis.

Authors:  R L Smyth; N M Croft; U O'Hea; T G Marshall; A Ferguson
Journal:  Arch Dis Child       Date:  2000-05       Impact factor: 3.791

Review 5.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

6.  Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia.

Authors:  D Peckham; S Crouch; H Humphreys; B Lobo; A Tse; A J Knox
Journal:  Thorax       Date:  1994-08       Impact factor: 9.139

Review 7.  Inclusion body myositis: clinical features and pathogenesis.

Authors:  Steven A Greenberg
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

8.  The relationship of systemic inflammation to prior hospitalization in adult patients with cystic fibrosis.

Authors:  David A Ngan; Pearce G Wilcox; May Aldaabil; Yuexin Li; Jonathon A Leipsic; Don D Sin; S F Paul Man
Journal:  BMC Pulm Med       Date:  2012-02-14       Impact factor: 3.317

9.  Myeloperoxidase and eosinophil cationic protein in serum and sputum during antibiotic treatment in cystic fibrosis patients with Pseudomonas aeruginosa infection.

Authors:  B Niggemann; T Stiller; K Magdorf; U Wahn
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

10.  Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis.

Authors:  Bradley S Quon; David A Ngan; Pearce G Wilcox; S F Paul Man; Don D Sin
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.